Breast Cancer Clinical Trial
Official title:
Genetic Counseling for Newly Diagnosed Breast Cancer Patients
RATIONALE: Genetics education and counseling may help patients make treatment decisions. It
is not yet known how genetic counseling or usual care influence patient treatment decisions
for breast cancer.
PURPOSE: This randomized clinical trial is studying how well genetic counseling works
compared to usual care in helping patients with newly diagnosed ductal carcinoma in situ,
stage I, stage II, or stage IIIA breast cancer make treatment decisions.
OBJECTIVES:
- Compare the impact of rapid genetic counseling (RGC) vs usual care on the medical
decisions of women with newly diagnosed ductal carcinoma in situ or stage I-IIIA breast
cancer.
- Compare the impact of these interventions on the quality of life and psychological well
being of these patients.
- Determine baseline factors that predict who is most and least likely to benefit from
RGC in patients undergoing these interventions.
- Compare the cost per quality adjusted life year saved from a societal perspective in
patients undergoing these interventions.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
participating site. Patients are randomized to 1 of 2 interventional arms.
- Arm I (rapid genetic counseling): Patients undergo a 1½ hour genetic counseling session
either in person or by telephone. Patients who undergo telephone counseling receive a
booklet of visual aids and educational materials. Patient preferences and values are
assessed immediately after counseling. Some patients may undergo BRCA1/2 status
determination. Patients undergo follow-up telephone interviews at 1, 6, and 12 months.
- Arm II (usual care): Patients receive a packet of breast cancer treatment educational
materials. Patient preferences and values are assessed 2 weeks later. Patients undergo
follow-up telephone interviews as in arm I.
In both arms, quality of life is assessed at baseline and at 1, 6, and 12 months.
After completion of the study, patients are followed periodically for 1 year.
PROJECTED ACCRUAL: A total of 360 patients will be accrued for this study.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |